Bolt Biotherapeutics (BOLT) Gets a Buy from Lake Street

Tip Ranks
2025.11.13 14:16
portai
I'm PortAI, I can summarize articles.

Lake Street analyst Chad Messer reiterated a Buy rating for Bolt Biotherapeutics, setting a price target of $75. The analyst has an average return of -0.3% and a 38.73% success rate. The general consensus on The Street is a Moderate Buy with a $29.33 average price target for Bolt Biotherapeutics.

Lake Street analyst Chad Messer reiterated a Buy rating on Bolt Biotherapeutics today and set a price target of $75.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

According to TipRanks, Messer is an analyst with an average return of -0.3% and a 38.73% success rate. Messer covers the Healthcare sector, focusing on stocks such as Coya Therapeutics, Inc., Oncolytics Biotech, and Bolt Biotherapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bolt Biotherapeutics with a $29.33 average price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.